Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
348 EUR | -0.57% |
|
+3.11% | -3.20% |
Jul. 08 | CAC40: will end in the red, despite easing OAT rates | CF |
Jul. 08 | That's not so bad, is it? | ![]() |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- The company presents an interesting fundamental situation from a short-term investment perspective.
Strengths
- Over the last twelve months, the sales forecast has been frequently revised upwards.
- For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
- Over the past four months, analysts' average price target has been revised upwards significantly.
- Consensus analysts have strongly revised their opinion of the company over the past 12 months.
- Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.
Weaknesses
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The company is highly valued given the cash flows generated by its activity.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-3.20% | 3.17B | B- | ||
-11.81% | 80.05B | B+ | ||
+22.75% | 3.52B | B- | ||
+18.58% | 1.74B | - | ||
-8.59% | 1.21B | - | ||
-38.07% | 1.02B | B | ||
-40.81% | 989M | C- | ||
-35.77% | 859M | - | ||
-9.04% | 839M | D+ | ||
-19.65% | 834M | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- VIRP Stock
- Ratings Virbac